Oncoprex® Delivery System

Genprex’s oncology program utilizes its systemic, non-viral Oncoprex® Delivery System that utilizes lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor genes deleted during the course of cancer development. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor.

Designed to Deliver Cancer-Fighting Genes Systemically

The platform allows for the intravenous delivery of various tumor suppressor genes, and potentially other genes, to achieve a therapeutic affect without the risk of toxicity often associated with viral delivery systems. Genprex believes this system allows for delivery of a number of cancer-fighting genes, alone or in combination with other cancer therapies, to combat multiple types of cancer.

Our lead drug candidate, Reqorsa® Gene Therapy, utilizes the ONCOPREX Delivery System to encapsulate the TUSC2 gene in positively charged lipoplexes that are attracted to negatively charged cancer cells. The lipoplexes then enter the cancer cells through selective endocytosis, a process by which cells take in substances from outside the cell by engulfing them in a vesicle.

The cationic (positive) charge of the lipoplexes helps to target cancer cells, which have a slight negative charge due to their high glycolytic rate. A Phase 1 clinical trial showed that intravenous REQORSA therapy selectively and preferentially targeted tumor cells, resulting in anticancer activity. The lipoplexes are non-immunogenic, allowing repetitive therapeutic dosing and providing extended half-life in the circulation.

To learn more about the scientific evidence, studies and the latest developments about the Genprex and its programs, please review our latest Investor Presentation, our press releases and SEC filings.